Mice Model Market

Mice Model Market Size, Growth Research Report By Model Type & Service (Model Type, (Inbred Mice, Genetically Engineered Mice, Hybrid/Congenic Mice, Outbred Mice), Service, (Breeding, Cryopreservation, Rederivation, Quarantine and Other Services)), By Technology (CRISPR/CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer and Other Technologies), By Therapeutic Area (Oncology, Metabolic Diseases, Immunology, Neurology, Cardiovascular Diseases and Other Therapeutic Diseases), By Application (Drug Discovery & Development, Research Application and Personalized Medicine) – Competitor Industry Analysis and Trends Forecast Till 2035

Forecast Period
2025 - 2035
CAGR
6.2%
2024 Market Size
$ 1.68 Billion
2035 Market Size
$ 3.25 Billion
Healthcare ● Updated May 2026 Report ID: MRFR/HC/20372-HCR | Pages: 128 | Author: Nidhi Mandole, Rahul Gotadki
Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Model Type (USD Billion)
      1. 4.1.1 Inbred Mice
      2. 4.1.2 Genetically Engineered Mice
      3. 4.1.3 Hybrid/Congenic Mice
      4. 4.1.4 Outbred Mice
    2. 4.2 Healthcare, BY Service (USD Billion)
      1. 4.2.1 Breeding
      2. 4.2.2 Cryopreservation
      3. 4.2.3 Rederivation
      4. 4.2.4 Quarantine
      5. 4.2.5 Other services
    3. 4.3 Healthcare, BY Technology (USD Billion)
      1. 4.3.1 CRISPR/CAS9
      2. 4.3.2 Microinjection
      3. 4.3.3 Embryonic Stem Cell Injection
      4. 4.3.4 Nuclear Transfer
      5. 4.3.5 Other Technologies
    4. 4.4 Healthcare, BY Therapeutic Area (USD Billion)
      1. 4.4.1 Oncology
      2. 4.4.2 Metabolic Diseases
      3. 4.4.3 Immunology
      4. 4.4.4 Neurology
      5. 4.4.5 Cardiovascular Diseases
      6. 4.4.6 Other Therapeutic Diseases
    5. 4.5 Healthcare, BY Application (USD Billion)
      1. 4.5.1 Drug Discovery & Development
      2. 4.5.2 Research Application
      3. 4.5.3 Personalized Medicine
    6. 4.6 Healthcare, BY End User (USD Billion)
      1. 4.6.1 Pharmaceutical & Biotechnology Companies
      2. 4.6.2 Academic & Research Institutes
      3. 4.6.3 CROS & CDMOS
    7. 4.7 Healthcare, BY Region (USD Billion)
      1. 4.7.1 North America
        1. 4.7.1.1 US
        2. 4.7.1.2 Canada
      2. 4.7.2 Europe
        1. 4.7.2.1 Germany
        2. 4.7.2.2 UK
        3. 4.7.2.3 France
        4. 4.7.2.4 Russia
        5. 4.7.2.5 Italy
        6. 4.7.2.6 Spain
        7. 4.7.2.7 Rest of Europe
      3. 4.7.3 APAC
        1. 4.7.3.1 China
        2. 4.7.3.2 India
        3. 4.7.3.3 Japan
        4. 4.7.3.4 South Korea
        5. 4.7.3.5 Malaysia
        6. 4.7.3.6 Thailand
        7. 4.7.3.7 Indonesia
        8. 4.7.3.8 Rest of APAC
      4. 4.7.4 South America
        1. 4.7.4.1 Brazil
        2. 4.7.4.2 Mexico
        3. 4.7.4.3 Argentina
        4. 4.7.4.4 Rest of South America
      5. 4.7.5 MEA
        1. 4.7.5.1 GCC Countries
        2. 4.7.5.2 South Africa
        3. 4.7.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Charles River Laboratories (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 The Jackson Laboratory (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Taconic Biosciences (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Envigo (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Harlan Laboratories (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Crown Bioscience (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Janvier Labs (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 InVivo Biosystems (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 GenOway (FR)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY MODEL TYPE
    4. 6.4 US MARKET ANALYSIS BY SERVICE
    5. 6.5 US MARKET ANALYSIS BY TECHNOLOGY
    6. 6.6 US MARKET ANALYSIS BY THERAPEUTIC AREA
    7. 6.7 US MARKET ANALYSIS BY APPLICATION
    8. 6.8 US MARKET ANALYSIS BY END USER
    9. 6.9 CANADA MARKET ANALYSIS BY MODEL TYPE
    10. 6.10 CANADA MARKET ANALYSIS BY SERVICE
    11. 6.11 CANADA MARKET ANALYSIS BY TECHNOLOGY
    12. 6.12 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA
    13. 6.13 CANADA MARKET ANALYSIS BY APPLICATION
    14. 6.14 CANADA MARKET ANALYSIS BY END USER
    15. 6.15 EUROPE MARKET ANALYSIS
    16. 6.16 GERMANY MARKET ANALYSIS BY MODEL TYPE
    17. 6.17 GERMANY MARKET ANALYSIS BY SERVICE
    18. 6.18 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    19. 6.19 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA
    20. 6.20 GERMANY MARKET ANALYSIS BY APPLICATION
    21. 6.21 GERMANY MARKET ANALYSIS BY END USER
    22. 6.22 UK MARKET ANALYSIS BY MODEL TYPE
    23. 6.23 UK MARKET ANALYSIS BY SERVICE
    24. 6.24 UK MARKET ANALYSIS BY TECHNOLOGY
    25. 6.25 UK MARKET ANALYSIS BY THERAPEUTIC AREA
    26. 6.26 UK MARKET ANALYSIS BY APPLICATION
    27. 6.27 UK MARKET ANALYSIS BY END USER
    28. 6.28 FRANCE MARKET ANALYSIS BY MODEL TYPE
    29. 6.29 FRANCE MARKET ANALYSIS BY SERVICE
    30. 6.30 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    31. 6.31 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA
    32. 6.32 FRANCE MARKET ANALYSIS BY APPLICATION
    33. 6.33 FRANCE MARKET ANALYSIS BY END USER
    34. 6.34 RUSSIA MARKET ANALYSIS BY MODEL TYPE
    35. 6.35 RUSSIA MARKET ANALYSIS BY SERVICE
    36. 6.36 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
    37. 6.37 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA
    38. 6.38 RUSSIA MARKET ANALYSIS BY APPLICATION
    39. 6.39 RUSSIA MARKET ANALYSIS BY END USER
    40. 6.40 ITALY MARKET ANALYSIS BY MODEL TYPE
    41. 6.41 ITALY MARKET ANALYSIS BY SERVICE
    42. 6.42 ITALY MARKET ANALYSIS BY TECHNOLOGY
    43. 6.43 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA
    44. 6.44 ITALY MARKET ANALYSIS BY APPLICATION
    45. 6.45 ITALY MARKET ANALYSIS BY END USER
    46. 6.46 SPAIN MARKET ANALYSIS BY MODEL TYPE
    47. 6.47 SPAIN MARKET ANALYSIS BY SERVICE
    48. 6.48 SPAIN MARKET ANALYSIS BY TECHNOLOGY
    49. 6.49 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA
    50. 6.50 SPAIN MARKET ANALYSIS BY APPLICATION
    51. 6.51 SPAIN MARKET ANALYSIS BY END USER
    52. 6.52 REST OF EUROPE MARKET ANALYSIS BY MODEL TYPE
    53. 6.53 REST OF EUROPE MARKET ANALYSIS BY SERVICE
    54. 6.54 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
    55. 6.55 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA
    56. 6.56 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    57. 6.57 REST OF EUROPE MARKET ANALYSIS BY END USER
    58. 6.58 APAC MARKET ANALYSIS
    59. 6.59 CHINA MARKET ANALYSIS BY MODEL TYPE
    60. 6.60 CHINA MARKET ANALYSIS BY SERVICE
    61. 6.61 CHINA MARKET ANALYSIS BY TECHNOLOGY
    62. 6.62 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
    63. 6.63 CHINA MARKET ANALYSIS BY APPLICATION
    64. 6.64 CHINA MARKET ANALYSIS BY END USER
    65. 6.65 INDIA MARKET ANALYSIS BY MODEL TYPE
    66. 6.66 INDIA MARKET ANALYSIS BY SERVICE
    67. 6.67 INDIA MARKET ANALYSIS BY TECHNOLOGY
    68. 6.68 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA
    69. 6.69 INDIA MARKET ANALYSIS BY APPLICATION
    70. 6.70 INDIA MARKET ANALYSIS BY END USER
    71. 6.71 JAPAN MARKET ANALYSIS BY MODEL TYPE
    72. 6.72 JAPAN MARKET ANALYSIS BY SERVICE
    73. 6.73 JAPAN MARKET ANALYSIS BY TECHNOLOGY
    74. 6.74 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
    75. 6.75 JAPAN MARKET ANALYSIS BY APPLICATION
    76. 6.76 JAPAN MARKET ANALYSIS BY END USER
    77. 6.77 SOUTH KOREA MARKET ANALYSIS BY MODEL TYPE
    78. 6.78 SOUTH KOREA MARKET ANALYSIS BY SERVICE
    79. 6.79 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
    80. 6.80 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA
    81. 6.81 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    82. 6.82 SOUTH KOREA MARKET ANALYSIS BY END USER
    83. 6.83 MALAYSIA MARKET ANALYSIS BY MODEL TYPE
    84. 6.84 MALAYSIA MARKET ANALYSIS BY SERVICE
    85. 6.85 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
    86. 6.86 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA
    87. 6.87 MALAYSIA MARKET ANALYSIS BY APPLICATION
    88. 6.88 MALAYSIA MARKET ANALYSIS BY END USER
    89. 6.89 THAILAND MARKET ANALYSIS BY MODEL TYPE
    90. 6.90 THAILAND MARKET ANALYSIS BY SERVICE
    91. 6.91 THAILAND MARKET ANALYSIS BY TECHNOLOGY
    92. 6.92 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA
    93. 6.93 THAILAND MARKET ANALYSIS BY APPLICATION
    94. 6.94 THAILAND MARKET ANALYSIS BY END USER
    95. 6.95 INDONESIA MARKET ANALYSIS BY MODEL TYPE
    96. 6.96 INDONESIA MARKET ANALYSIS BY SERVICE
    97. 6.97 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
    98. 6.98 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA
    99. 6.99 INDONESIA MARKET ANALYSIS BY APPLICATION
    100. 6.100 INDONESIA MARKET ANALYSIS BY END USER
    101. 6.101 REST OF APAC MARKET ANALYSIS BY MODEL TYPE
    102. 6.102 REST OF APAC MARKET ANALYSIS BY SERVICE
    103. 6.103 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
    104. 6.104 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA
    105. 6.105 REST OF APAC MARKET ANALYSIS BY APPLICATION
    106. 6.106 REST OF APAC MARKET ANALYSIS BY END USER
    107. 6.107 SOUTH AMERICA MARKET ANALYSIS
    108. 6.108 BRAZIL MARKET ANALYSIS BY MODEL TYPE
    109. 6.109 BRAZIL MARKET ANALYSIS BY SERVICE
    110. 6.110 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
    111. 6.111 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA
    112. 6.112 BRAZIL MARKET ANALYSIS BY APPLICATION
    113. 6.113 BRAZIL MARKET ANALYSIS BY END USER
    114. 6.114 MEXICO MARKET ANALYSIS BY MODEL TYPE
    115. 6.115 MEXICO MARKET ANALYSIS BY SERVICE
    116. 6.116 MEXICO MARKET ANALYSIS BY TECHNOLOGY
    117. 6.117 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA
    118. 6.118 MEXICO MARKET ANALYSIS BY APPLICATION
    119. 6.119 MEXICO MARKET ANALYSIS BY END USER
    120. 6.120 ARGENTINA MARKET ANALYSIS BY MODEL TYPE
    121. 6.121 ARGENTINA MARKET ANALYSIS BY SERVICE
    122. 6.122 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
    123. 6.123 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA
    124. 6.124 ARGENTINA MARKET ANALYSIS BY APPLICATION
    125. 6.125 ARGENTINA MARKET ANALYSIS BY END USER
    126. 6.126 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODEL TYPE
    127. 6.127 REST OF SOUTH AMERICA MARKET ANALYSIS BY SERVICE
    128. 6.128 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    129. 6.129 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA
    130. 6.130 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    131. 6.131 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    132. 6.132 MEA MARKET ANALYSIS
    133. 6.133 GCC COUNTRIES MARKET ANALYSIS BY MODEL TYPE
    134. 6.134 GCC COUNTRIES MARKET ANALYSIS BY SERVICE
    135. 6.135 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
    136. 6.136 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA
    137. 6.137 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    138. 6.138 GCC COUNTRIES MARKET ANALYSIS BY END USER
    139. 6.139 SOUTH AFRICA MARKET ANALYSIS BY MODEL TYPE
    140. 6.140 SOUTH AFRICA MARKET ANALYSIS BY SERVICE
    141. 6.141 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
    142. 6.142 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA
    143. 6.143 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    144. 6.144 SOUTH AFRICA MARKET ANALYSIS BY END USER
    145. 6.145 REST OF MEA MARKET ANALYSIS BY MODEL TYPE
    146. 6.146 REST OF MEA MARKET ANALYSIS BY SERVICE
    147. 6.147 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
    148. 6.148 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA
    149. 6.149 REST OF MEA MARKET ANALYSIS BY APPLICATION
    150. 6.150 REST OF MEA MARKET ANALYSIS BY END USER
    151. 6.151 KEY BUYING CRITERIA OF HEALTHCARE
    152. 6.152 RESEARCH PROCESS OF MRFR
    153. 6.153 DRO ANALYSIS OF HEALTHCARE
    154. 6.154 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    155. 6.155 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    156. 6.156 SUPPLY / VALUE CHAIN: HEALTHCARE
    157. 6.157 HEALTHCARE, BY MODEL TYPE, 2024 (% SHARE)
    158. 6.158 HEALTHCARE, BY MODEL TYPE, 2024 TO 2035 (USD Billion)
    159. 6.159 HEALTHCARE, BY SERVICE, 2024 (% SHARE)
    160. 6.160 HEALTHCARE, BY SERVICE, 2024 TO 2035 (USD Billion)
    161. 6.161 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    162. 6.162 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    163. 6.163 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
    164. 6.164 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
    165. 6.165 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    166. 6.166 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    167. 6.167 HEALTHCARE, BY END USER, 2024 (% SHARE)
    168. 6.168 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    169. 6.169 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.2.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.2.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.2.6 BY END USER, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.3.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.3.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.3.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.3.6 BY END USER, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.4.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.4.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.4.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.4.6 BY END USER, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.5.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.5.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.5.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.5.6 BY END USER, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.6.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.6.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.6.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.6.6 BY END USER, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.7.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.7.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.7.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.7.6 BY END USER, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.8.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.8.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.8.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.8.6 BY END USER, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.9.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.9.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.9.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.9.6 BY END USER, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.10.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.10.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.10.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.10.6 BY END USER, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.11.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.11.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.11.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.11.6 BY END USER, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.12.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.12.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.12.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.12.6 BY END USER, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.13.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.13.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.13.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.13.6 BY END USER, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.14.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.14.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.14.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.14.6 BY END USER, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.15.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.15.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.15.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.15.6 BY END USER, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.16.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.16.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.16.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.16.6 BY END USER, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.17.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.17.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.17.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.17.6 BY END USER, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.18.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.18.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.18.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.18.6 BY END USER, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.19.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.19.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.19.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.19.6 BY END USER, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.20.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.20.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.20.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.20.6 BY END USER, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.21.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.21.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.21.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.21.6 BY END USER, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.22.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.22.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.22.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.22.6 BY END USER, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.23.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.23.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.23.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.23.6 BY END USER, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.24.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.24.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.24.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.24.6 BY END USER, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.25.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.25.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.25.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.25.6 BY END USER, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.26.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.26.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.26.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.26.6 BY END USER, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.27.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.27.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.27.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.27.6 BY END USER, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.28.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.28.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.28.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.28.6 BY END USER, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.29.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.29.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.29.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.29.6 BY END USER, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY MODEL TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY SERVICE, 2025-2035 (USD Billion)
      3. 7.30.3 BY TECHNOLOGY, 2025-2035 (USD Billion)
      4. 7.30.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion)
      5. 7.30.5 BY APPLICATION, 2025-2035 (USD Billion)
      6. 7.30.6 BY END USER, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1
Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample

Mice Model Market Segmentation

Mice Model Market By Model Type (USD Billion, 2025-2035)

  • Inbred Mice
  • Genetically Engineered Mice
  • Hybrid/Congenic Mice
  • Outbred Mice

Mice Model Market By Service (USD Billion, 2025-2035)

  • Breeding
  • Cryopreservation
  • Rederivation
  • Quarantine
  • Other services

Mice Model Market By Technology (USD Billion, 2025-2035)

  • CRISPR/CAS9
  • Microinjection
  • Embryonic Stem Cell Injection
  • Nuclear Transfer
  • Other Technologies

Mice Model Market By Therapeutic Area (USD Billion, 2025-2035)

  • Oncology
  • Metabolic Diseases
  • Immunology
  • Neurology
  • Cardiovascular Diseases
  • Other Therapeutic Diseases

Mice Model Market By Application (USD Billion, 2025-2035)

  • Drug Discovery & Development
  • Research Application
  • Personalized Medicine

Mice Model Market By End User (USD Billion, 2025-2035)

  • Mice Model Market & Biotechnology Companies
  • Academic & Research Institutes
  • CROS & CDMOS
Share::
WhatsApp icon
LinkedIn icon
X (Twitter) icon
ChatGPT icon
Perplexity icon
Request Free Sample

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.